## ALGN: Align Technology, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.76 indicates fundamental undervaluation. Caution: overbought RSI (74).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($148.26)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Align Technology stock gains as competitor raises prices**
- Source: Investing.com | 20251206T090823 | Bullish | Relevance: 99%
- Align Technology (NASDAQ:ALGN) stock rose after Stifel reiterated a Buy rating and $200 price target, following news that competitor Angelalign plans an 8-9% price increase on its clear aligner offering. This move could strengthen Align Technology's market position, especially with its pending zero refinement plan priced at approximately $850. Recent survey results indicate that Align's new plan could encourage practices to return to or increase their volume with Align Technology.

**2. Align Technology Announces Invisalign® System With Mandibular Advancement Featuring Occlusal Blocks for Class II Skeletal and Dental Correction**
- Source: Yahoo Finance | 20251209T020854 | Bullish | Relevance: 99%
-  Align Technology has launched the Invisalign® System with mandibular advancement featuring occlusal blocks for Class II skeletal and dental correction. This new solution is designed for growing patients with Class II malocclusions, offering simultaneous mandible advancement and teeth alignment. The system utilizes integrated solid occlusal blocks for durability and improved treatment efficiency, particularly in cases with deep bites.

**3. Align Technology (Nasdaq: ALGN) launches Class II mandibular advancement in Asia-Pacific**
- Source: Stock Titan | 20251209T021244 | Bullish | Relevance: 99%
-  Align Technology (Nasdaq: ALGN) has launched its Invisalign System with mandibular advancement featuring occlusal blocks in Asia-Pacific. This innovative solution addresses Class II skeletal and dental correction in growing patients by simultaneously advancing the mandible and aligning teeth, offering an efficient and predictable treatment option for a common orthodontic problem. The product is now commercially available in several Asia-Pacific countries, expanding Align's portfolio for Class II malocclusions.

**4. ALGN Stock Rises on Thailand Launch of Invisalign With MAOB**
- Source: TradingView | 20251209T120804 | Bullish | Relevance: 99%
-  Align Technology (ALGN) has launched its Invisalign System with mandibular advancement feat. occlusal blocks (MAOB) in Thailand, causing ALGN stock to rise. This system expands its Class II treatment portfolio for growing patients with malocclusions. The company aims to capture a larger share of the global malocclusion market, which affects 60-75% of the population and is projected to grow significantly.

**5. Align Technology Stock Gains Competitive Edge from Rival’s Pricing Move**
- Source: AD HOC NEWS | 20251208T071135 | Bullish | Relevance: 99%
- Align Technology (NASDAQ: ALGN) is projected to gain market share in the clear aligner market due to a recent price increase from its competitor, Angelalign. Align's strong Q3 2025 results, outperforming revenue and EPS expectations, further solidify its position, and its "Zero Refinement" plan is becoming more attractive. Analyst ratings remain positive, indicating potential upside, with Stifel and Piper Sandler reiterating "Buy" and "Overweight" ratings respectively, and dental practice surveys confirming a favorable environment for Align’s market recuperation.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (+0.7%)
- Blackrock Inc.: 6.9% (-3.4%)
- Ninety One UK Ltd: 6.3% (+136.6%)
- Capital Internationa: 4.2% (+88.6%)
- State Street Corpora: 4.0% (-1.3%)

### Key Risks

1. High beta (1.86) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.76 indicates undervaluation relative to growth. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.4B |
| Beta | 1.86 |
| 52W Range | $122.00 - $246.19 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.76 |
| Forward P/E | 14.4 |
| Current P/E | 15.5 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 6.0% to 7.2% (+1.2% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 at 1.2% confirms short-term momentum alignment. AM_20 at 9.3% shows strong absolute momentum above own 20MA. Outperforming sector by 10.6pp, stock-specific strength. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (1.65), confirming momentum. RSI overbought at 74, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.17% (CS: 91) | Strong |
| RSI_14 | 73.8 | Overbought |
| MACD Histogram | 1.65 | Bullish |
| vs SMA20 | 1.093x | Above |
| vs SMA50 | 1.149x | Above |
| vs SMA200 | 0.984x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $157.68
- **Stop Loss:** $148.26 (6.0% risk)
- **Target:** $176.52 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 53
- **Position Value:** $8,357.04
- **Portfolio %:** 8.36%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-04 (Est: $2.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.41 | $2.61 | +8.4% |
| 2025Q2 | $2.57 | $2.49 | -3.3% |
| 2025Q1 | $1.99 | $2.13 | +7.1% |
| 2024Q4 | $2.45 | $2.44 | -0.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*